PRIME-ROSE

PRIME-ROSE has now been working hard for a year, and our fight against cancer continues ❤️🩹 PRIME-ROSE shares the ambition of the EU Cancer Mission to save and improve 3 million lives by 2030 and fully endorses the need for sustainable and affordable access to new and innovative drugs for cancer patients in Europe. Help us reach our goal by leaving a comment! #primerose #cancermission #fightingcancer #medicine #personalisedmedicine

This claim is false. 🙅🚫 The work we do is diverse. PRIME-ROSE consists of eight closely aligned and fully integrated work packages: 1️⃣WP: Data Aggregation 2️⃣WP: Control Cohorts 3️⃣WP: Expansion Cohorts 4️⃣WP: Drug Repurposing 5️⃣WP: EU Implementation 6️⃣WP: Social Innovation 7️⃣WP: Project Management 8️⃣WP: Dissemination Read more about the work packages: https://lnkd.in/d9YYwJcu

Did you know that 25% of women and 31% of men in Europe will be affected by cancer? 23% of EMA/FDA approved new drugs in 2023 were for oncology indications and that 88% of these were targeted agents. Our vision in PRIME-ROSE is to enhance access to precision cancer medicine that prolongs life at the best quality possible for all cancer patients. 💉🧬   #primerose #MissionCancer #HorizonEU #fightingcancer #medicine #personalisedmedicine

Happy be here and present PRIME-ROSE and discuss Nordic-Baltic collaboration at the Northern Insights meeting.

The challenge of accessing costly new treatments has driven health systems to seek innovative solutions. 💡🔬 To explore these solutions, three researchers of PRIME-ROSE teamed up with other experts to establish a platform for sharing ideas and best practices. Their newly published editorial, Towards continued and affordable accessibility of innovative drugs: sustainable development and efficient use of medicines, highlights these ideas and solutions; e.g. addressing over-treatment, reducing waste, In-house drug development and manufacturing and repurposing of medicines. 👉 Read more: https://lnkd.in/dDTjbkJV Atse Huisman (Zorgverzekeraars Nederland and LUMC), Denise van den Berg (Treatmeds Foundation), Saco de Visser (FAST), Bettina Ryll (Melanoma Patient Network Europe and Stockholm School of Economics), and Sahar Barjesteh van Waalwijk van Doorn-Khosrovani (LUMC, CZ) #primerose #cancermission #fightingcancer #medicine #personalisedmedicine #cancer #research #healthcare #DRUP 

PRIME-ROSE has been active for a year now, and we continue progressing. 🚀This EU-funded project is dedicated to enhancing access to precision cancer medicine across Europe. Swipe to learn more about PRIME-ROSE – and follow our journey on LinkedIn. 👉 Keep on reading here: https://lnkd.in/dsn8kkTH #primerose #cancermission #fightingcancer #medicine #personalisedmedicine

💡Innovation is key in the fight against cancer. PRIME-ROSE, funded by the EU Horizon Cancer Mission, is working to reshape precision cancer medicine by improving access to new, affordable treatments for patients across Europe. By focusing on innovative clinical trials, PRIME-ROSE aims to bridge the gap in access to life-saving drugs, especially for patients with rare tumors and those who have exhausted standard treatments. Together, we’re working towards the EU Cancer Mission's goal of saving 3 million lives by 2030. 💪 #primerose #cancermission #fightingcancer #medicine #personalisedmedicine

Nordic-Baltic Conference in Clinical Trials 2024 brought innovative ideas to increase competitiveness as a region of 33 M people. PCM4EU - Personalised Cancer Medicine for all EU citizens and PRIME-ROSE experiences and plans were smoothly integrated in the discussion by Bettina Ryll and Katriina Jalkanen #clinicaltrials #NordiBalticCollaboration

🔬 What an exciting fall for PCM and therefore a recap of ESMO Congress at Barcelona! Precision medicine made it to the Presidential Symposium III with Andrea Botticelli presenting results from the ROME trial. The ROME trial showed that CGP-based targeted therapy significantly improved response rates and progression-free survival without added toxicity. Our PRIME-ROSE family of DRUP-like clinical trials was also vividly present: 🎯 Real world experience & patients' participation in multidisciplinary consortiums: the results from the PRIME-ROSE Community Advisory Board, PRO reporting – Bettina Ryll 🎯 1542MO - Mapping the scale of off-label use in oncology: an important step in harmonising access – Hans Timmer 🎯 The PRIME-ROSE project demonstrated the benefits of collaboration in DLCT trials, accelerating research and expanding evidence generation. 🎯 The FINPROVE trial emphasized the value of molecular profiling in guiding treatment decisions, leading to longer survival in certain patient groups. The future of cancer treatment is personalized, powered by genomics! 🧬 Read more about the Rome trial: https://lnkd.in/dbURkZ3N Read more about how Rediscovery Protocol-like clinical trials facilitate access to precision oncology: https://lnkd.in/dhAkNhgg      #primerose #cancermission #fightingcancer #medicine #personalisedmedicine #ESMO2024 #DRUP 

Personalized medicine is a rapidly evolving field and the ethical conversation is essential- follow-up for the coming symposium report